Cargando…

Markers of Antioxidant Defense in Patients with Type 2 Diabetes

Aims. Diabetes is considered a state of increased oxidative stress. This study evaluates blood concentrations of selected markers of antioxidant defense in patients with type 2 diabetes. Methods. The study included 80 type 2 diabetes patients and 79 apparently healthy controls. Measured markers incl...

Descripción completa

Detalles Bibliográficos
Autores principales: Gawlik, K., Naskalski, J. W., Fedak, D., Pawlica-Gosiewska, D., Grudzień, U., Dumnicka, P., Małecki, M. T., Solnica, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4657103/
https://www.ncbi.nlm.nih.gov/pubmed/26640613
http://dx.doi.org/10.1155/2016/2352361
_version_ 1782402337261748224
author Gawlik, K.
Naskalski, J. W.
Fedak, D.
Pawlica-Gosiewska, D.
Grudzień, U.
Dumnicka, P.
Małecki, M. T.
Solnica, B.
author_facet Gawlik, K.
Naskalski, J. W.
Fedak, D.
Pawlica-Gosiewska, D.
Grudzień, U.
Dumnicka, P.
Małecki, M. T.
Solnica, B.
author_sort Gawlik, K.
collection PubMed
description Aims. Diabetes is considered a state of increased oxidative stress. This study evaluates blood concentrations of selected markers of antioxidant defense in patients with type 2 diabetes. Methods. The study included 80 type 2 diabetes patients and 79 apparently healthy controls. Measured markers included ferric reducing ability of plasma (FRAP), reduced glutathione (GSH), glutathione peroxidase (GPx), glutathione reductase (GR), γ-glutamyltransferase (GGT) and uric acid serum, and plasma and/or hemolysate levels. Results. FRAP, uric acid, CRP, and GGT levels were significantly higher in patients with diabetes. Plasma and hemolysate GR was significantly higher whereas GPx activity was significantly lower in patients with diabetes. There were no significant differences in antioxidant defense markers between patients with and without chronic diabetes complications. Fasting serum glucose correlated with plasma GPx, plasma and hemolysate GR, FRAP, and serum GGT, and HbA1c correlated with serum GGT. Only FRAP and serum uric acid were significantly higher in obese (BMI > 30 kg/m(2)) patients with diabetes than in nonobese patients. Conclusions. Some components of antioxidant defense such as GR, uric acid, and GGT are increased in patients with type 2 diabetes. However, the whole system cannot compensate for an enhanced production of ROS as reflected by the trend toward decreased erythrocytes GSH.
format Online
Article
Text
id pubmed-4657103
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-46571032015-12-06 Markers of Antioxidant Defense in Patients with Type 2 Diabetes Gawlik, K. Naskalski, J. W. Fedak, D. Pawlica-Gosiewska, D. Grudzień, U. Dumnicka, P. Małecki, M. T. Solnica, B. Oxid Med Cell Longev Research Article Aims. Diabetes is considered a state of increased oxidative stress. This study evaluates blood concentrations of selected markers of antioxidant defense in patients with type 2 diabetes. Methods. The study included 80 type 2 diabetes patients and 79 apparently healthy controls. Measured markers included ferric reducing ability of plasma (FRAP), reduced glutathione (GSH), glutathione peroxidase (GPx), glutathione reductase (GR), γ-glutamyltransferase (GGT) and uric acid serum, and plasma and/or hemolysate levels. Results. FRAP, uric acid, CRP, and GGT levels were significantly higher in patients with diabetes. Plasma and hemolysate GR was significantly higher whereas GPx activity was significantly lower in patients with diabetes. There were no significant differences in antioxidant defense markers between patients with and without chronic diabetes complications. Fasting serum glucose correlated with plasma GPx, plasma and hemolysate GR, FRAP, and serum GGT, and HbA1c correlated with serum GGT. Only FRAP and serum uric acid were significantly higher in obese (BMI > 30 kg/m(2)) patients with diabetes than in nonobese patients. Conclusions. Some components of antioxidant defense such as GR, uric acid, and GGT are increased in patients with type 2 diabetes. However, the whole system cannot compensate for an enhanced production of ROS as reflected by the trend toward decreased erythrocytes GSH. Hindawi Publishing Corporation 2016 2015-11-10 /pmc/articles/PMC4657103/ /pubmed/26640613 http://dx.doi.org/10.1155/2016/2352361 Text en Copyright © 2016 K. Gawlik et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Gawlik, K.
Naskalski, J. W.
Fedak, D.
Pawlica-Gosiewska, D.
Grudzień, U.
Dumnicka, P.
Małecki, M. T.
Solnica, B.
Markers of Antioxidant Defense in Patients with Type 2 Diabetes
title Markers of Antioxidant Defense in Patients with Type 2 Diabetes
title_full Markers of Antioxidant Defense in Patients with Type 2 Diabetes
title_fullStr Markers of Antioxidant Defense in Patients with Type 2 Diabetes
title_full_unstemmed Markers of Antioxidant Defense in Patients with Type 2 Diabetes
title_short Markers of Antioxidant Defense in Patients with Type 2 Diabetes
title_sort markers of antioxidant defense in patients with type 2 diabetes
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4657103/
https://www.ncbi.nlm.nih.gov/pubmed/26640613
http://dx.doi.org/10.1155/2016/2352361
work_keys_str_mv AT gawlikk markersofantioxidantdefenseinpatientswithtype2diabetes
AT naskalskijw markersofantioxidantdefenseinpatientswithtype2diabetes
AT fedakd markersofantioxidantdefenseinpatientswithtype2diabetes
AT pawlicagosiewskad markersofantioxidantdefenseinpatientswithtype2diabetes
AT grudzienu markersofantioxidantdefenseinpatientswithtype2diabetes
AT dumnickap markersofantioxidantdefenseinpatientswithtype2diabetes
AT małeckimt markersofantioxidantdefenseinpatientswithtype2diabetes
AT solnicab markersofantioxidantdefenseinpatientswithtype2diabetes